Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy - Université de Lille
Article Dans Une Revue Parkinsonism & Related Disorders Année : 2022

Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy

Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy.

Résumé

Background Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment for late-stage Parkinson's disease (PD) but had not been evaluated in levodopa-responsive patients with the parkinsonian variant of multiple system atrophy (MSA-P) and motor fluctuations. We aimed to assess the safety of LCIG in MSA-P patients. Methods In a retrospective, single-center study, we analyzed clinical and treatment-related data for all patients with MSA-P or PD treated with LCIG between December 2004 and November 2017. Adverse events (AEs) were classified into three classes: AEs related to gastrointestinal effects or to the PEG-J procedure, AEs related to the device, and AEs related to the pharmacological effect of LCIG. Results 7 MSA-P and 63 PD patients had been treated with LCIG for a median [interquartile range] period of 31 [16;43] and 19 [8;45] months, respectively. There were no significant intergroup differences in safety. Enteral nutrition was introduced at the same time as LCIG treatment in 4 (57%) MSA-P patients. In the MSA-P and PD groups, LCIG was associated with a better Global Clinical Impression score and discontinuation of oral anti-parkinsonian drugs (in 43% and 27% of cases, respectively). Conclusions LCIG treatment is feasible in MSA-P patients with severe motor complications. The safety profile is similar to that seen in PD.
Fichier principal
Vignette du fichier
S1353802022001493.pdf (189 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04151650 , version 1 (22-07-2024)

Licence

Identifiants

Citer

A. S. Blaise, Elodie Cuvelier, N. Carrière, David Devos, F. Moreau, et al.. Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy. Parkinsonism & Related Disorders, 2022, Parkinsonism and Related Disorders, 100, pp.41-44. ⟨10.1016/j.parkreldis.2022.05.018⟩. ⟨hal-04151650⟩

Collections

UNIV-LILLE
18 Consultations
3 Téléchargements

Altmetric

Partager

More